Join the Mantle Cell Lymphoma group to help and get support from people like you.
Mantle Cell Lymphoma News
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
PRINCETON, N.J.--(BUSINESS WIRE) May 30, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Breyanzi ® (lisocabtagene ...
His Cancer Journey Shows Health Dangers Firefighters Face
FRIDAY, May 10, 2024 – For 14 years, David Perez fought fires in South Florida, thinking he was in peak physical shape. Then a routine physical turned up anomalies in his blood work that turned his...
ASH: Ibrutinib-Venetoclax Beneficial for Relapsed/Refractory Lymphoma
THURSDAY, Dec. 14, 2023 – For patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), ibrutinib combined with venetoclax provides a progression-free survival benefit, according to a...
FDA Approves Jaypirca (pirtobrutinib) for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
Jaypirca is the first BTK inhibitor of any kind specifically approved for patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor In the BRUIN Phase 1/2 trial, covalent...
Calquence Tablet Formulation Approved in the US Across Current indications
New formulation can be co-administered with gastric acid-reducing agents Tablet offers equivalent efficacy, safety and consistent dosing compared to current capsule 5 August 2022 – AstraZeneca’s n...
FDA Approves Tecartus (brexucabtagene autoleucel) as the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma
SANTA MONICA, Calif.--(BUSINESS WIRE)--Jul. 24, 2020-- Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tec...
FDA Approves Brukinsa (zanubrutinib) for the Treatment of Mantle Cell Lymphoma
CAMBRIDGE, Mass. and BEIJING, China, Nov. 14, 2019 (GLOBE NEWSWIRE) – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
FDA Approves Calquence (acalabrutinib) for Adults with Mantle Cell Lymphoma
October 31, 2017 – The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at...
Ask a question
To post your own question to this support group, sign in or create an account.